What is PCRX's current stock price?

As of now, PCRX is trading at $24.33, with a daily change of -0.25%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

PCRX Stock Analysis & IQ Rating | Pacira BioSciences I

PCRX

Pacira BioSciences I

$24.33

-$0.06 | -0.25%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$27.99

MKT CAP

$1.05B

52W Low

$16.29

VOL

$296.77K

P/E Ratio

52.17

AVG VOL

$663.35K

RSI

60.14

TREND

Sideways

PCRX Stock IQ

Login to see Pacira BioSciences I (PCRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

PCRX Target Price

Login to display

Strengths

PCRX Rewards

Earnings are forecast to grow

Chart

$22.02 (+10.49%)

$25.36 (-4.06%)

$23.48 (+3.62%)

$17.81 (+36.61%)

1year

6month

3month

1month

PCRX Risk Level

PCRX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

PCRX Analysts Opinion

PCRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

PCRX Analysts Opinion

PCRX Analysts opinion is positive and also has improved from the past 3 months

PCRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

100%

PCRX Street Sentiment

PCRX Street Sentiment is bullish and have positive views on the near-term outlook

PCRX Performance Sentiment

Sentiments overview associated with PCRX events and the stock performance.

69%

31%

Positive

Negative

9 out of 13
events present

4 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$23.78

Resistance
Price

$21.01

Current Price Range

$24.36

Show methods +

Linked to PCRX

IQ

Close Price

Change

JNJ

4.10

202.51

+1.23%

PCRX Latest Analysis +

Pacira BioSciences gains as investor calls for full sales process.

Tue Nov 11, 2025

$24.12 | +4.55%

Momentum

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences. BRISBANE Calif. Nov. 11 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences Inc. (Nasdaq: PCRX) the industry leader in its commitment to deliver innovative non-opioid pain therapies to transform the lives of patients today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

Tue Nov 11, 2025

$24.12 | +4.55%

Activity

Potential

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences Inc. to Immediately Explore a Sale of the Business. DOMA Controls 6.8% of Pacira Common StockPCRX) (".Pacira".) today sent a letter to the Board of Directors of Pacira (the ".Board".) urging the Board to hire bankers and conduct a full sale process of the company. The letter can be downloaded .The full text of the letter follows:th 2025To the Board of Directors of Pacira:As you are aware DOMA Perpetu

Tue Nov 11, 2025

$24.12 | +4.55%

Activity

Earnings

Potential

Pacira BioSciences Non-GAAP EPS of $0.70 beats by $0.05 revenue of $179.5M misses by $2.83M.

Thu Nov 6, 2025

$21.10 | -3.43%

Earnings

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million Validating Its Tunable Drug Delivery Platform. AmacaThera receives AMT-143 AmacaThera'.s long-acting non-opioid anesthetic for post-operative painAMT-143 leverages AmacaThera'.s breakthrough tunable hydrogel platform delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program and Pacira will fund clinical development manufacturi

Tue Nov 4, 2025

$22.44 | +1.13%

Activity

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6 2025. BRISBANE Calif. Oct. 30 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences Inc. (Nasdaq: PCRX) the industry leader in its commitment to deliver innovative non-opioid pain therapies to transform the lives of patients today announced that it will report its third quarter financial results after the close of the United States markets on Thursday November 6 2025. Following the release the company will host a live conference

Thu Oct 30, 2025

$21.27 | +1.24%

Potential

FAQ About PCRX Stock Insights

What is PCRX current stock price?

What are PCRX stock strengths?

What is PCRX Risk Level?

What is PCRX market cap and volume?

What is PCRX current Stock IQ?

Should I buy PCRX stock right now?

Is PCRX a Strong Buy right now?

What does a 'Strong Buy' rating mean for PCRX?

What does a 'Strong Sell' rating mean for PCRX?

What factors influence PCRX's Stock IQ?

Explore our PCRX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored PCRX Stock Strategies
Effective Risk Management

FIND US ON

Receive our PCRX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

PCRX

Pacira BioSciences I

Current Price

$24.33

-$0.06 | -0.25%

52W High

$27.99

MKT CAP

$1.05B

52W Low

$16.29

VOL

$296.77K

P/E Ratio

52.17

AVG VOL

$663.35K

RSI

60.14

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

PCRX Rewards

Earnings are forecast to grow

Linked to PCRX

Symbol

IQ

Close

Change

JNJ

4.10

202.51

+1.23%

PCRX Stock IQ

Login to unlock Pacira BioSciences I (PCRX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$22.02 (+10.49%)

$25.36 (-4.06%)

$23.48 (+3.62%)

$17.81 (+36.61%)

1year

6month

3month

1month

PCRX Analysts Opinion

PCRX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

PCRX Analysts Opinion

PCRX Analysts opinion is positive and also has improved from the past 3 months

PCRX Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential.

69%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

100%

PCRX Street Sentiment

PCRX Street Sentiment is bullish and have positive views on the near-term outlook

PCRX Risk Level

PCRX has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

PCRX Performance Sentiment

Sentiments overview associated with PCRX events and the stock performance.

69%

31%

Positive

Negative

9 out of 13
events present

4 out of 13
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$23.78

Resistance
Price

$21.01

Current Price Range

$24.36

Show methods +

PCRX Latest Analysis

Pacira BioSciences gains as investor calls for full sales process.

Tue Nov 11, 2025

$24.12 | +4.55%

Momentum

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences. BRISBANE Calif. Nov. 11 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences Inc. (Nasdaq: PCRX) the industry leader in its commitment to deliver innovative non-opioid pain therapies to transform the lives of patients today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

Tue Nov 11, 2025

$24.12 | +4.55%

Activity

Potential

DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences Inc. to Immediately Explore a Sale of the Business. DOMA Controls 6.8% of Pacira Common StockPCRX) (".Pacira".) today sent a letter to the Board of Directors of Pacira (the ".Board".) urging the Board to hire bankers and conduct a full sale process of the company. The letter can be downloaded .The full text of the letter follows:th 2025To the Board of Directors of Pacira:As you are aware DOMA Perpetu

Tue Nov 11, 2025

$24.12 | +4.55%

Activity

Earnings

Potential

Pacira BioSciences Non-GAAP EPS of $0.70 beats by $0.05 revenue of $179.5M misses by $2.83M.

Thu Nov 6, 2025

$21.10 | -3.43%

Earnings

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million Validating Its Tunable Drug Delivery Platform. AmacaThera receives AMT-143 AmacaThera'.s long-acting non-opioid anesthetic for post-operative painAMT-143 leverages AmacaThera'.s breakthrough tunable hydrogel platform delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program and Pacira will fund clinical development manufacturi

Tue Nov 4, 2025

$22.44 | +1.13%

Activity

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6 2025. BRISBANE Calif. Oct. 30 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences Inc. (Nasdaq: PCRX) the industry leader in its commitment to deliver innovative non-opioid pain therapies to transform the lives of patients today announced that it will report its third quarter financial results after the close of the United States markets on Thursday November 6 2025. Following the release the company will host a live conference

Thu Oct 30, 2025

$21.27 | +1.24%

Potential

Discover PCRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of PCRX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our PCRX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

PCRX Stock trends

PCRX Stock performance

PCRX Stock analysis

PCRX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing PCRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing PCRX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

PCRX Stock Analysis & IQ Rating | Pacira BioSciences I

PCRX Stock IQ

PCRX Target Price

PCRX Risk Level

PCRX Analysts Opinion

PCRX Street Sentiment

PCRX Performance Sentiment

Technical Price Levels

Explore our PCRX Stock insights

Receive our PCRX Daily Alerts

PCRX Stock IQ

PCRX Street Sentiment

PCRX Risk Level

Technical Price Levels

Discover PCRX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of PCRX. We're here to help you make informed investment decisions today.

Receive our PCRX Daily Alerts

PCRX Runner Alarm